Program Chairs

Nancy Kwan Man, MBBS, PhD
Director, Clinical and Translational Research Laboratory
Director, Laboratory for Liver Transplantation and Liver Cancer
Deputy Director, Laboratory for Organ Transplantation and Regeneration
Professor, Department of Surgery
The University of Hong Kong

R. Mark Ghobrial, M.D., Ph.D., FACS, FRCS (Ed)
Sherrie and Alan Conover Endowed Chair
Director, Sherrie & Alan Conover Center for Liver Disease & Transplantation
Chief, Liver Transplantation Surgery
Director, Immunobiology Research Center
Professor of Surgery
Weill Cornell Medical College

Taizo Hibi, MD, PhD, FACS
Professor and Chairman
Department of Pediatric Surgery and Transplantation
Kumamoto University Graduate School of Medical Sciences
Director, Organ Transplant Center
Kumamoto University Hospital

Gonzalo Sapisochin, MD, PhD, MSc
Assistant Professor of Surgery
Abdominal Transplant and HPB Surgical Oncology
University Health Network
University of Toronto

Brief Introduction

Transplant oncology is a new concept encompassing multiple disciplines of transplantation medicine and oncology to take hepatobiliary cancer treatment and research to the next level. The Consensus Conference in Rotterdam will convene worldwide experts and opinion leaders in transplant surgery, radiology and oncology, hepatology and immunology to discuss the frontiers and future perspectives of multidisciplinary management of hepatobiliary malignancies.

The main topics will include liver transplantation for hepatocellular carcinoma, cholangiocarcinoma, colorectal and neuroendocrine liver metastases, pediatric malignancy, therapies for cancer recurrence after liver transplantation and role of novel chemotherapeutic and biological agents to enhance transplantation outcomes.

Learning objectives

1. Understand the gap between the current practice and the future of transplant oncology
2. Update selection criteria, prediction models and emerging indications
3. Identify novel biologic, chemotherapeutic, radiologic, and immunotherapeutic approaches
08:00  Welcome Remark
Wojciech Polak, MD, PhD Erasmus MC – Rotterdam, The Netherlands

08:05 – 09:20  Introductory Lectures
Chairs:
Nancy Kwan Man, MBBS, PhD The University of Hong Kong – Hong Kong, China
Gonzalo Sapisochin, MD Toronto General Hospital – Toronto, Canada
Patrizia Burra, MD, PhD Padova University Hospital – Padova, Italy

08:05 – 08:20  Transplant oncology – Current perspectives
John Roberts, MD University of California San Francisco – San Francisco, CA, USA

08:20 – 08:50  The future of transplant oncology: Bridging the gap
Vincenzo Mazzaferro, MD Fondazione IRCCS Instituto Nazionale dei Tumori di Milano – Milan, Italy
Bruno Sangro, MD, PhD The University of Navarra School of Medicine – Pamplona, Spain

08:50 – 09:20  Novel biologic, chemotherapeutic, radiologic, and immunotherapeutic approaches
R. Mark Ghobrial MD, PhD, FRCS Methodist Hospital – Houston, TX, USA
Milind Javle, MD University of Texas MD Anderson Cancer Center – Houston, TX, USA

09:30 – 13:00  Consensus Conference Lectures

PART I
Chairs:
Vincenzo Mazzaferro, MD Fondazione IRCCS Istituto Nazionale dei Tumori di Milano – Milan, Italy
Taizo Hibi, MD, PhD, FACS Kumamoto University Graduate School of Medical Sciences – Kumamoto, Japan
Milind Javle, MD University of Texas MD Anderson Cancer Center – Houston, TX, USA

09:30 – 10:00  The update of liver transplantation for HCC
Western experience
Francis Yao, MD University of California San Francisco – San Francisco, CA, USA
Eastern experience
Avi Soin, MD Medanta – The Medicity, India

10.00 – 10.30  The update of liver transplantation for CCA
Julie Heimbach, MD Mayo Clinic Rochester – Rochester, ME, USA
Gonzalo Sapisochin, MD Toronto General Hospital – Toronto, Canada
10:30 – 10:45  Coffee Break

PART II

Chairs:
R. Mark Ghobrial MD, PhD, FRCS Methodist Hospital – Houston, TX, USA
Wojciech Polak, MD, PhD Erasmus MC – Rotterdam, The Netherlands
John Fung, MD, PhD University of Chicago Medicine Transplant Institute – Chicago, IL, USA

10:45 – 11:15  **Emerging indications for liver transplantation: colorectal and neuroendocrine liver metastases**
James Eason, MD Methodist University Transplant – Memphis, TN, USA
Pal Dag Line, MD, PhD Oslo University Hospital – Oslo, Norway

11:15 – 11:45  **Pediatric transplant oncology**
Mohamed Rela, MD Gleneagles Global Hospital – Chennai, India
Taizo Hibi, MD, PhD, FACS Kumamoto University Graduate School of Medical Sciences – Kumamoto, Japan

11:45 – 12:00  Coffee Break

PART III

Chairs:
Jan Lerut, MD, PhD University Hospitals Saint Luc – Brussels, Belgium
Valeria Mas, M.S., PhD, FAST Methodist University Hospital – Memphis, TN, USA
Yaman Tokat, MD Florence Nightingale Hospital – Istanbul, Turkey

12:00 – 12:30  **Post-transplant management for cancer recurrence**
Sherrie Bhoori, MD National Cancer Institute – Milan, Italy
Shusen Zheng, MD, PhD Zhejiang University – Hangzhou, China

12:30 – 13:00  **The changes of transplant indications**
DAA therapies
Marina Berenguer, MD Hospital La Fe – Valencia, Spain
NASH/HCC
Patrizia Burra, MD, PhD Padova University Hospital – Padova, Italy

13:00 – 14:00  Lunch Break

14:00 – 15:30  **Working Group Discussions**
1. Liver transplantation for HCC
   - Updates on the selection criteria
   - Prediction models
   - Downstaging and bridging therapies
   - Should small tumors be treated by ablation and reserve OLT for large cancers?

Group leaders:
Vincenzo Mazzaferro, MD Fondazione IRCCS Istituto Nazionale dei Tumori di Milano – Milan, Italy
Neil Mehta, PhD University of California: San Francisco – San Francisco, CA, USA
Avi Soin, MD Medanta – The Medicity, India

Working Group members:
Shusen Zheng, MD, PhD Zhejiang University – Hangzhou, China
Jan Ijzermans, MD, PhD Erasmus MC – Rotterdam, The Netherlands
John Roberts, MD University of California San Francisco – San Francisco, CA, USA
François Durand, MD Hospital Beaujon – Clichy, France
Nobuhisa Akamatsu, MD, PhD The University of Tokyo – Tokyo, Japan
Francis Yao, MD University of California San Francisco - San Francisco, CA, USA
Wojciech Polak, MD, PhD Erasmus MC – Rotterdam, The Netherlands
Prashant Bhangui, MBBS, MS Medanta Institute of Liver Transplantation and Regenerative Medicine – Gurgaon, India

2. Liver transplantation for CCA /mixed HCC/CCA
   - Hilar CCA
   - Intrahepatic CCA
   - Mixed HCC/CCA (Outcomes, diagnostic and prognostic tools, adjuvant treatments)

Group Leaders:
Julie Heimbach, MD Mayo Clinic Rochester – Rochester, ME, USA
Gonzalo Sapisochin, MD Toronto General Hospital – Toronto, Canada
Milind Javle, MD University of Texas MD Anderson Cancer Center – Houston, TX, USA

Working Group Members:
R. Mark Ghobrial MD, PhD, FRCS Methodist Hospital – Houston, TX, USA
Masayuki Ohtsuka, MD, PhD Chiba University – Chiba, Japan
Darwish-Murad Sarwa, MD Erasmus MC – Rotterdam, The Netherlands
Daniel Maluf, MD Methodist University Hospital – Memphis, TN, USA
Gabriela Berlakovich, MD Medical University of Vienna – Vienna, Austria
Jan Lerut, MD, PhD University Hospitals Saint Luc Catholic of the University of Louvain – Louvain, Belgium
3. Less common tumors of transplant oncology
   a. Colorectal liver metastasis
   b. Neuroendocrine liver metastasis
   c. Tumors in the pediatric population and other rare tumor

Group Leaders:
Mohamed Rela, MD Gleneagles Global Hospital – Chennai, India
Taizo Hibi, MD, PhD, FACS Kumamoto University Graduate School of Medical Sciences Kumamoto, Japan
James Eason, MD Methodist University Transplant – Memphis, TN, USA

Group Members:
Pal Dag Line, MD, PhD Oslo University Hospital – Oslo, Norway
John Fung, MD, PhD University of Chicago Medicine Transplant Institute – Chicago, IL, USA
Seisuke Sakamoto, MD, PhD National Center for Child Health and Development – Tokyo, Japan
Nazia Selzner, MD, PHD University of Toronto – Toronto, Canada

4. Post-transplant management
   a. Tailored immunosuppression for cancer recipients
   b. Cancer recurrence prediction models and surveillance strategies
   c. New adjuvant therapies for recurrence after OLT
      (chemotherapy, immunotherapy, new biological treatment and radiotherapy)

Group Leaders:
Marina Berenguer, MD Hospital La Fe – Valencia, Spain
Patrizia Burra, MD, PhD Padova University Hospital – Padova, Italy
Herold Metselaar, MD, PhD Erasmus MC – Rotterdam, The Netherlands

Group members:
Nancy Kwan Man, MBBS, PhD The University of Hong Kong – Hong Kong, China
Sherrie Bhooi, MD National Cancer Institute – Milan, Italy
Valeria Mas, M.S., PhD, FAST Methodist University Hospital – Memphis, TN, USA
Bruno Sangro, MD, PhD The University of Navarra School of Medicine, Pamplona, Spain
Masahiro Ohira, PhD Hiroshima University Hospital – Higashihiroshima, Japan
Luc van der Laan, PhD Erasmus MC – Rotterdam, The Netherlands

15:30 – 16:00   Coffee Break
16:00 – 18:00   Working Group Presentations with Statements
18:00 – 18:30   Summary
CONTINUING MEDICAL EDUCATION (CME) CREDITS

The ILTS 2019 Consensus Conference: Transplant Oncology - The Future of Multidisciplinary Management, Rotterdam, Netherlands, 07/02/2019-07/02/2019 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 7 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section I) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.


www.ilts.org
ILTS Headquarters
ILTS Headquarters
K.I.T. Group GmbH
Association & Conference Management
Kurfürstendamm 71
10709 Berlin
Germany
Phone: +49 (0) 30 24603 349
Fax: +49 (0) 30 24603 200
ilts@ilts.org
www.ilts.org

Conference Venue
Hilton Rotterdam
Weena 10
3012 CM Rotterdam
Netherlands

Session Rooms
Le Jardin, Maaskant, Coolingsel Suite, Kruiskade, Conrad Suite

Registration
Please register here by February 6, 2019, 23:59 CET (GMT+2)

Should you require further assistance please don’t hesitate to contact the ILTS Registration Department:
ilts-consensusregistration@kit-group.org
Hotline: +49 30 24603 410

Accommodation at Conference Venue Hotel
All participants are responsible for their own accommodation. The Conference organizers have reserved a limited contingent of rooms in advance for attendees at the venue hotel. Please contact the hotel and let them know that you wish to book a room out of the contingent.

To book a room please click here